Future studies should identify optimal AMH levels in conjunction with such factors as age, type of cancer, and treatment regimens, along with the ideal post-chemotherapy AMH timeframe (e.g., 24 or 36 months) for achieving a healthy live birth following fertility preservation. The gene discussed is AMH; the disease is cancer.